UnknownPhase 2NCT01696422

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

Studying Dengue fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Butantan Institute
Principal Investigator: Alexander R Precioso, MD, PhD
Instituto Butantan
Intervention: Dengue 1,2,3,4 (attenuated) vaccine(biological)
Enrollment: 300 enrolled
Eligibility: 18-59 years · All sexes
Timeline: 2013 – 2020

Study locations (2)

Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Collaborators

Banco Nacional de Desenvolvimento Economico e Social · Fundação de Amparo à Pesquisa do Estado de São Paulo · Butantan Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01696422 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials